Research programme: p56lck inhibitors - Celltech

Drug Profile

Research programme: p56lck inhibitors - Celltech

Alternative Names: p56lck inhibitors research programme - Celltech

Latest Information Update: 20 Sep 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Celltech R&D
  • Class
  • Mechanism of Action Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Autoimmune disorders; Transplant rejection

Most Recent Events

  • 02 May 2001 Celltech Chiroscience Discovery is now called Celltech R&D
  • 02 Feb 2000 Medeva has been merged into Celltech Chiroscience, which is now called Celltech Group
  • 22 Oct 1999 Celltech has merged with Chiroscience to form Celltech Chiroscience
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top